Denmark rejects Gilead and Eisai cancer drugs

Two cancer drugs were recently deemed too costly for the Danish Medicines Agency, which continued its trend at its November meeting of passing on expensive treatments – though one drug made it through due to the ”serious nature” of its indication.

Gilead and Eisai have had to leave empty-handed from Denmark this month | Photo: Stine Rasmussen/Ritzau Scanpix

On Wednesday, while Danish pharmaceutical firm Lundbeck was celebrating its general-use approval for migraine drug Vyepti, US-based Gilead and Japanese Eisai were left empty-handed after the Danish Medicines Agency’s released notes form its monthly meeting.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs